ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing Immediate Immunity against each of the three causes of calf scours (E. coli, coronavirus, and rotavirus).
BörsenkürzelICCC
Name des UnternehmensImmuCell Corp
IPO-datumMay 01, 1987
CEOMr. Michael F. Brigham
Anzahl der mitarbeiter69
WertpapierartOrdinary Share
GeschäftsjahresendeMay 01
Addresse56 Evergreen Drive
StadtPORTLAND
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl04103
Telefon12078782770
Websitehttps://immucell.com/
BörsenkürzelICCC
IPO-datumMay 01, 1987
CEOMr. Michael F. Brigham
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten